TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7549809

Group type: COMPARATOR
Intervention: Smokers and patients with oral leukoplakia or erythroplakia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients with oral trauma
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients with diabetes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pregnant women
Number of subjects: 0
Study: 2005316

Group type: EXPERIMENTAL
Intervention: Reactive dye exposure (black GR and orange 3R)
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Reactive dye exposure
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: RAST-inhibition tests of black GR
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Orange 3R RAST-inhibition tests
Number of subjects: 309
Study: 7022275

Group type: EXPERIMENTAL
Intervention: Sustained release metoprolol 200 mg once daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional formulation metoprolol 100 mg bd
Number of subjects: 30
Study: 31416685

Group type: EXPERIMENTAL
Intervention: Radiotherapy (70 Gy, with chemotherapy if N1-2)
Number of subjects: 68

Group type: COMPARATOR
Intervention: TORS plus neck dissection (with or without adjuvant chemoradiotherapy)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 68

Group type: COMPARATOR
Intervention: TORS plus neck dissection
Number of subjects: 68
Study: 28886024

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) 25 mg/day with metformin (MET) 2 g/day for 3 months
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (Plac) with metformin (MET) 2 g/day for 3 months
Number of subjects: 24
Study: 25845992

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel 40 mg/m² and carboplatin AUC 2 with concurrent radiotherapy 66 Gy in 33 fractions
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel 60 mg/m² and carboplatin AUC 2 with concurrent radiotherapy 66 Gy in 33 fractions
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel 40 mg/m²
Number of subjects: 10
Study: 23453583

Group type: EXPERIMENTAL
Intervention: Tosedostat 120 mg once daily for 6 months
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Tosedostat 240 mg once daily for 2 months followed by 120 mg for 4 months
Number of subjects: 76
Study: 21345662

Group type: EXPERIMENTAL
Intervention: Plant stanols
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Plant stanol ester
Number of subjects: 182

Group type: COMPARATOR
Intervention: Plant sterols
Number of subjects: 182

Group type: COMPARATOR
Intervention: Plant sterol ester
Number of subjects: 182
Study: 20187484

Group type: EXPERIMENTAL
Intervention: Restrictive protocol for intravenous fluid administration (group A, 65 pts)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Liberal fluid administration policy (group B, 65 pts)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 130
Study: 17363767

Group type: EXPERIMENTAL
Intervention: GSTP1, EPHX1, and MMP1 polymorphisms
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: GSTP1 and EPHX1 single-nucleotide polymorphisms
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: EPHX1 His139Arg single-nucleotide polymorphism
Number of subjects: 282
Study: 14744971

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent (2.7 microg/mm2)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Bare stent
Number of subjects: 190
Study: 11348960

Group type: EXPERIMENTAL
Intervention: 10-mL/kg loading dose of perflubron
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 20-mL/kg loading dose of perflubron
Number of subjects: 16
Study: 9205821

Group type: EXPERIMENTAL
Intervention: Single dose of JTP-4819 30 mg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Single dose of JTP-4819 60 mg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Single dose of JTP-4819 120 mg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Multiple doses of JTP-4819 60 mg three times daily for 7 days
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Multiple doses of JTP-4819 60 mg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Multiple doses of JTP-4819
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Single dose of JTP-4819
Number of subjects: 28
Study: 8202233

Group type: EXPERIMENTAL
Intervention: Autologous cryoprecipitate
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 6
Study: 2885827

Group type: EXPERIMENTAL
Intervention: Almitrine-raubasine combination
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 31541704

Group type: EXPERIMENTAL
Intervention: Evaluation of the Perception of Physical Activity (EPPA) questionnaire
Number of subjects: 548

Group type: EXPERIMENTAL
Intervention: EPPA Beliefs subscale
Number of subjects: 548
Study: 29573167

Group type: EXPERIMENTAL
Intervention: Active treatment with transcranial pulsed electromagnetic fields (T-PEMFs), 30 minutes daily for eight consecutive weeks.
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo treatment (control group).
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Active treatment with T-PEMFs.
Number of subjects: 97
Study: 27194717

Group type: EXPERIMENTAL
Intervention: Intravenous alanyl-glutamine (0.5 g·kg(‐1)·day(‐1))
Number of subjects: 10

Group type: COMPARATOR
Intervention: No supplement (control group)
Number of subjects: 10
Study: 25635977

Group type: EXPERIMENTAL
Intervention: Telmisartan (40 mg a day)
Number of subjects: 41
Study: 24088687

Group type: EXPERIMENTAL
Intervention: Integration of family planning services into HIV clinics
Number of subjects: 5682

Group type: COMPARATOR
Intervention: Referral to family planning clinics (Control)
Number of subjects: 5682
Study: 21120597

Group type: EXPERIMENTAL
Intervention: Media system A (G-IVF (TM) v5 PLUS/ G-1(TM) v5 PLUS)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Media system B (Universal IVF medium/EmbryoAssist (TM))
Number of subjects: 110
Study: 18667327

Group type: EXPERIMENTAL
Intervention: HA-group (blood priming containing FFP and human albumin 20%)
Number of subjects: 20

Group type: COMPARATOR
Intervention: FFP-group (blood priming with fresh frozen plasma)
Number of subjects: 20
Study: 16533195

Group type: EXPERIMENTAL
Intervention: Prolotherapy injections and exercises
Number of subjects: 110
Study: 12773728

Group type: EXPERIMENTAL
Intervention: Tobacco specific survey introduction
Number of subjects: 3996

Group type: COMPARATOR
Intervention: General health survey introduction
Number of subjects: 3996
Study: 10822743

Group type: EXPERIMENTAL
Intervention: 2-session recognition of intoxication training program
Number of subjects: 45

Group type: COMPARATOR
Intervention: Attention-placebo control group
Number of subjects: 45
Study: 8863992

Group type: EXPERIMENTAL
Intervention: Interferon (IFN) treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonresponders
Number of subjects: 0
Study: 2072069

Group type: EXPERIMENTAL
Intervention: Breast self examination (BSE) practice
Number of subjects: 1315

Group type: EXPERIMENTAL
Intervention: Conservative surgery eligibility
Number of subjects: 1315
Study: 6191137

Group type: EXPERIMENTAL
Intervention: Propranolol, 80 mg three times daily
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Metoprolol, 100 mg two times daily
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control, without concurrent drugs
Number of subjects: 8
Study: 30782343

Group type: EXPERIMENTAL
Intervention: Lomustine-temozolomide therapy (100 mg/m2 on day 1 plus temozolomide 100–200 mg/m2 per day on days 2–6 of the 6-week course)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Standard temozolomide therapy (75 mg/m2 per day concomitant to radiotherapy followed by six courses of temozolomide 150–200 mg/m2 per day on the first 5 days of the 4-week course)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Lomustine-temozolomide therapy
Number of subjects: 141

Group type: COMPARATOR
Intervention: Standard temozolomide therapy
Number of subjects: 141
Study: 30035339

Group type: EXPERIMENTAL
Intervention: Late mild cognitive impairment (LMCI)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Early mild cognitive impairment (EMCI)
Number of subjects: 79
Study: 27370892

Group type: EXPERIMENTAL
Intervention: Betamethasone 8 mg
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 24923476

Group type: EXPERIMENTAL
Intervention: Linearity assumption for converting MR signal intensity to gadolinium concentration
Number of subjects: 17

Group type: COMPARATOR
Intervention: Nonlinear conversion method for converting MR signal intensity to gadolinium concentration
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Model-free parameters using both conversion methods
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Modeled parameters using SPGR equations
Number of subjects: 17
Study: 22674586

Group type: EXPERIMENTAL
Intervention: Cyclamen europaeum extract
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 29
Study: 19696051

Group type: EXPERIMENTAL
Intervention: Standard Bridging Technique (SBT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Traditional Open Technique (TOT)
Number of subjects: 100
Study: 18753091

Group type: EXPERIMENTAL
Intervention: Sufentanil 2.5 microg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sufentanil 5 microg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sufentanil 7.5 microg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bupivacaine only (0 microg sufentanil)
Number of subjects: 60
Study: 16471120

Group type: EXPERIMENTAL
Intervention: Predictive model based on clinical data including presence of diabetes mellitus and ECG leads with abnormal Q waves.
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Validation of the predictive model in a separate subset of patients.
Number of subjects: 137
Study: 12766388

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin patches (20 mg/24 h) administered intermittently
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin patches (20 mg/24 h) administered continuously
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 9831410

Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg tds
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 0
Study: 8697930

Group type: EXPERIMENTAL
Intervention: Plasma exchange (PE) plus D‐penicillamine (group I)
Number of subjects: 29

Group type: COMPARATOR
Intervention: D‐penicillamine alone (group II)
Number of subjects: 29
Study: 2568970

Group type: EXPERIMENTAL
Intervention: Betamethasone-dixyrazine
Number of subjects: 40

Group type: COMPARATOR
Intervention: High-dose metoclopramide
Number of subjects: 40
Study: 809046

Group type: EXPERIMENTAL
Intervention: Briserin (0.1 mg reserpine, 5 mg clopamide, 0.5 mg dihydroergocristin/per tablet)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Briserin
Number of subjects: 20
Study: 30930609

Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT) with trauma-focused emotion regulation skills (TARGET)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Cognitive Behavior Therapy (CBT) without trauma-focused emotion regulation skills
Number of subjects: 29
Study: 27513260

Group type: EXPERIMENTAL
Intervention: Monosymptomatic nocturnal enuresis (NE) patients
Number of subjects: 38

Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 38
Study: 24725369

Group type: EXPERIMENTAL
Intervention: Physiotherapy with whole body vibration
Number of subjects: 49

Group type: COMPARATOR
Intervention: Physiotherapy alone
Number of subjects: 49
Study: 24183127

Group type: EXPERIMENTAL
Intervention: Nicotine patch (21 mg)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 119
Study: 20632263

Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Bupivacaine (preoperative or postoperative)
Number of subjects: 159
Study: 18259100

Group type: EXPERIMENTAL
Intervention: Intravenous alfacalcidol (mean dose 3.63 +/- 1.71 microg/week)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Intravenous alfacalcidol
Number of subjects: 185
Study: 16632892

Group type: EXPERIMENTAL
Intervention: Cr-enriched yeast (400 microg Cr/d)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 14635746

Group type: EXPERIMENTAL
Intervention: Hedrocel implants with autologous cancellous bone graft
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Solid block implant
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Autologous tricortical iliac crest bone graft
Number of subjects: 24
Study: 12196612

Group type: EXPERIMENTAL
Intervention: Web-based resource guide for service providers and a 'survival guide' for substance users
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Training intervention for injection drug users to serve as peer mentors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Educational intervention for day care teaching staff on asthma awareness
Number of subjects: 0
Study: 9385614

Group type: EXPERIMENTAL
Intervention: Clomipramine (12.5 mg, intravenous, single dose)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Moderate weight loss in subjects with obesity
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Baseline plasma leptin concentrations
Number of subjects: 19
Study: 7878638

Group type: EXPERIMENTAL
Intervention: Methacholine (Mch) infusion (0.1‐0.8‐4.0 micrograms/min)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP) infusion (0.5‐2.5‐10 micrograms/min)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Pre-infusion baseline
Number of subjects: 7
Study: 3225660

Group type: EXPERIMENTAL
Intervention: Weaning at 1700 g
Number of subjects: 60

Group type: COMPARATOR
Intervention: Weaning at 1800 g
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Weaning at 1700 g (birth weight ≤ 1000 g)
Number of subjects: 60
Study: 2035313

Group type: EXPERIMENTAL
Intervention: Budesonide 200 micrograms
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Budesonide 800 micrograms
Number of subjects: 33
Study: 1000139

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perphenazine
Number of subjects: 0
Study: 31584739

Group type: EXPERIMENTAL
Intervention: AZD9977 (50, 150, and 300 mg, twice daily for 8 days)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: AZD9977
Number of subjects: 27
Study: 28668251

Group type: EXPERIMENTAL
Intervention: Bicycle train intervention (daily cycling with study staff to and from school)
Number of subjects: 54
Study: 26426609

Group type: EXPERIMENTAL
Intervention: Telephone call performed (Group A)
Number of subjects: 300

Group type: COMPARATOR
Intervention: No telephone call (Group B)
Number of subjects: 300
Study: 23616506

Group type: EXPERIMENTAL
Intervention: Whole walnuts (85 g)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Nut skins (5.6 g)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Nut oil (51 g)
Number of subjects: 15

Group type: COMPARATOR
Intervention: De-fatted nutmeat (34 g)
Number of subjects: 15
Study: 21158885

Group type: EXPERIMENTAL
Intervention: Intermittent photic stimulation (IPS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 30
Study: 19619360

Group type: EXPERIMENTAL
Intervention: Personal Contact (PC) program
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: Internet-based program (IT)
Number of subjects: 690
Study: 17185301

Group type: EXPERIMENTAL
Intervention: BoNT‐A injections
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 40
Study: 15020604

Group type: COMPARATOR
Intervention: AAWD alone
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: AAWD and ketoconazole (400 mg orally tid)
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: AAWD and ketoconazole
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Deferred treatment with ketoconazole
Number of subjects: 260
Study: 11278149

Group type: EXPERIMENTAL
Intervention: Physostigmine; specific dosage and duration not mentioned
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified; no control intervention mentioned
Number of subjects: 0
Study: 9727818

Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine (12.5 mg)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine (25 mg)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Yohimbine (5.4 mg)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Indomethacin (50 mg)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Ibuprofen (600 mg)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Caffeine (250 mg)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Methylphenidate (5 mg)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Midodrine (5 mg)
Number of subjects: 35
Study: 8001526

Group type: EXPERIMENTAL
Intervention: Colour coded displays
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monochrome displays
Number of subjects: 0
Study: 3175472

Group type: EXPERIMENTAL
Intervention: Ivermectin (150 or 200 micrograms/kg)
Number of subjects: 39
Study: 31077667

Group type: EXPERIMENTAL
Intervention: Hydrogen (H2) dissolved in irrigation solution
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional solution (Control)
Number of subjects: 32
Study: 28275066

Group type: EXPERIMENTAL
Intervention: Pulsed Biphasic (PB) shocks
Number of subjects: 134

Group type: COMPARATOR
Intervention: Biphasic Truncated Exponential (BTE) shocks
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Both PB and BTE shocks
Number of subjects: 134
Study: 26008873

Group type: EXPERIMENTAL
Intervention: Partial weight‐supported treadmill training (PWSTT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Conventional gait training (CGT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nonexercising PD group
Number of subjects: 60
Study: 24088965

Group type: EXPERIMENTAL
Intervention: Volar locking plate
Number of subjects: 130

Group type: COMPARATOR
Intervention: Conventional percutaneous fixation
Number of subjects: 130
Study: 22254118

Group type: EXPERIMENTAL
Intervention: Spirulina (19 g daily)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Soybean (19 g daily)
Number of subjects: 33
Study: 19638081

Group type: EXPERIMENTAL
Intervention: Low residue test meals with 4L polyethylene glycol (TM-PEG 4L)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Clear liquid diet with 4L polyethylene glycol
Number of subjects: 214
Study: 17045910

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 14501380

Group type: EXPERIMENTAL
Intervention: 200 microg selenized yeast
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: 400 microg selenized yeast
Number of subjects: 514

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: Selenized yeast (200 or 400 microg)
Number of subjects: 514
Study: 10716539

Group type: EXPERIMENTAL
Intervention: Sibutramine 15 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 8785152

Group type: EXPERIMENTAL
Intervention: Bair-Hugger group (active skin surface warming with an upper body cover)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no intraoperative warming device)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Bair-Hugger group
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study: 1434338

Group type: EXPERIMENTAL
Intervention: Borage oil (Glandol)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (palm seed oil)
Number of subjects: 12
Study: 3881125

Group type: EXPERIMENTAL
Intervention: 0.1% betamethasone disodium phosphate
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: 0.5% prednisolone disodium phosphate
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: 5% tolmetin sodium dihydrate
Number of subjects: 71
Study: 31478309

Group type: EXPERIMENTAL
Intervention: Nurse-driven targeted HIV screening with routine diagnostic testing
Number of subjects: 8
Study: 29807890

Group type: EXPERIMENTAL
Intervention: CRT-ON
Number of subjects: 787

Group type: COMPARATOR
Intervention: CRT-OFF
Number of subjects: 787
Study: 27509222

Group type: EXPERIMENTAL
Intervention: Hemoglobin drop of at least 1g/dL
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Higher hemoglobin concentrations by discharge
Number of subjects: 433

Group type: COMPARATOR
Intervention: Pulmonary artery catheter (PAC) use
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Hospital length of stay
Number of subjects: 433
Study: 25720616

Group type: EXPERIMENTAL
Intervention: Personal genetic information (apoE genotype-based health advice)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group (no personal genetic information)
Number of subjects: 107
Study: 23665124

Group type: EXPERIMENTAL
Intervention: Local infiltration (150ml 0.2% ropivacaine/1ml 1:1000 adrenaline/30mg ketorolac)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Single shot femoral nerve block (30ml 0.2% ropivacaine)
Number of subjects: 40
Study: 20844378

Group type: EXPERIMENTAL
Intervention: Sevoflurane + 60% N2O
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Propofol + 60% N2O
Number of subjects: 28
Study: 18564797

Group type: EXPERIMENTAL
Intervention: Intrathecal midazolam
Number of subjects: 672
Study: 15992237

Group type: EXPERIMENTAL
Intervention: Honey dressing
Number of subjects: 32

Group type: COMPARATOR
Intervention: EUSOL dressing
Number of subjects: 32
Study: 12888056

Group type: EXPERIMENTAL
Intervention: Dry Eye Syndrome (DES) defined as clinically diagnosed DES or severe symptoms (dryness and irritation constantly or often)
Number of subjects: 39876

Group type: EXPERIMENTAL
Intervention: Age-adjusted prevalence of DES
Number of subjects: 39876

Group type: COMPARATOR
Intervention: Comparison of DES prevalence among different ethnic groups
Number of subjects: 39876

Group type: COMPARATOR
Intervention: Education level and DES prevalence
Number of subjects: 39876

Group type: COMPARATOR
Intervention: Geographic differences in DES prevalence
Number of subjects: 39876
Study: 10329858

Group type: EXPERIMENTAL
Intervention: Estring (2 mg estradiol)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control (no estrogen treatment)
Number of subjects: 108